Shopping Cart
- Remove All
- Your shopping cart is currently empty
Olorinab (APD 371) (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $51 | In Stock | |
5 mg | $122 | In Stock | |
10 mg | $197 | In Stock | |
25 mg | $397 | In Stock | |
50 mg | $589 | 6-8 weeks |
Description | Olorinab (APD 371) (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2. |
Targets&IC50 | CB2 (human):(EC50)6.2 nM |
In vitro | A comprehensive in vitro profile of Olorinab (APD 371) (6) demonstrates single-digit nanomolar potency and full intrinsic efficacy across all species assessed. It is highly selective for CB2 over CB1 in both binding and functional assays and induces efficient receptor internalization (~106% relative to the CB1/2 agonist CP55,940) in CHO cells expressing HA-tagged rat CB2, suggesting it can drive agonist-induced receptor recycling[1]. |
In vivo | Olorinab (APD 371) significantly increases paw withdrawal thresholds at doses ≥3 mg/kg PO (ED50=2.3 mg/kg), with its analgesic effects likely mediated via activity at CB2 receptors[1]. A single dose of Olorinab (APD 371) (10 mg/kg, PO) inhibits paw withdrawal threshold for up to 4 hours after administration. |
Alias | APD 371 |
Molecular Weight | 357.41 |
Formula | C18H23N5O3 |
Cas No. | 1268881-20-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 180 mg/mL (503.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.